Cardiol Therapeutics Inc. SEC filings CRDL
Cardiol Therapeutics Inc. has 188 filings in SEC EDGAR's recent list, going back to Mar 29, 2017. Its latest annual report, Form 40-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-10/A | Filing | Sep 16, 2026 | — |
| F-X | Filing | Sep 10, 2026 | — |
| F-10 | Filing | Sep 10, 2026 | — |
| F-X | Filing | Nov 5, 2025 | — |
| F-10 | Form f-10 | Nov 5, 2025 | — |
| F-10/A | Filing | Jul 12, 2024 | — |
| F-X | Form f-x | Jul 8, 2024 | — |
| F-10 | Filing | Jul 5, 2024 | — |
| F-10POS | Filing | Feb 8, 2022 | — |
| F-10/A | Filing | Feb 8, 2022 | — |
| F-X | Filing | Jan 26, 2022 | — |
| F-10 | Filing | Jan 26, 2022 | — |
| S-8 | Employee stock plan registration | Jan 18, 2022 | — |
| S-8 POS | Filing | Jan 18, 2022 | — |
| S-8 | Employee stock plan registration | Aug 19, 2021 | — |
| F-10/A | Filing | Aug 3, 2021 | — |
| F-X | Filing | Jul 8, 2021 | — |
| F-10 | Filing | Jul 8, 2021 | — |
Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRDL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- Oakville, Ontario, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1702123
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.